Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20801640 | 0.85 | MEN1 (0.40) | DNM1MEN1KMT2AALDH1A1HTT | |
| SCHEMBL19371885 | 0.80 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1TSHRKDM4E | |
| SCHEMBL13997591 | 0.78 | PRMT3 (0.39) | DNM1MEN1KMT2AALDH1A1USP2 | |
| SCHEMBL22382538 | 0.78 | DNM1 (0.36) | DNM1MEN1KMT2AALDH1A1USP2 | |
| SCHEMBL17450515 | 0.78 | MAPT (0.36) | MEN1KMT2AALDH1A1HTTTSHR | |
| SCHEMBL8227224 | 0.78 | KDM4E (0.46) | DNM1MEN1KMT2AALDH1A1USP2 | |
| SCHEMBL8741153 | 0.78 | MEN1 (0.48) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL1827225 | 0.78 | MEN1 (0.54) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL10111497 | 0.76 | CA1 (0.43) | TSHRKDM4E | |
| SCHEMBL2127728 | 0.76 | MCL1 (0.48) | DNM1MEN1KMT2ATSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782493-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170266303-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | PURDUE RESEARCH FOUNDATION | 2017-09-21 | — | — | US | disclosed |
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170151340-A1 | Conjugates Containing Hydrophilic Spacer Linkers | ENDOCYTE INC (US) | 2017-06-01 | — | — | US | disclosed |
| US-9662402-B2 | Drug delivery conjugates containing unnatural amino acids and methods for using | ENDOCYTE, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9636413-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160361376-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (IN) | 2016-12-15 | — | — | US | disclosed |
| US-20160287731-A1 | Compounds for Positron Emission Tomography | ENDOCYTE, INC | 2016-10-06 | — | — | US | disclosed |
| US-20140073761-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | ENDOCYTE, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140066594-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | ENDOCYTE, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140058063-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | ENDOCYTE, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140058064-A1 | MULTI-DRUG LIGAND CONJUGATES | ENDOCYTE, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20130184435-A1 | MULTI-DRUG LIGAND CONJUGATES | ENDOCYTE, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130116195-A1 | Binding ligand linked drug delivery conjugates of tubulysins | LEAMON CHRISTOPHER PAUL (US) | 2013-05-09 | — | — | US | disclosed |
| US-20120270791-A1 | Methods and Compositions for Treating and Diagnosing Kidney Disease | LEAMON CHRISTOPHER PAUL (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120065149-A1 | Vitamin receptor binding drug delivery conjugates | VLAHOV IONTCHO R (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120022245-A1 | FOLATE TARGETING OF NUCLEOTIDES | PURDUE RESEARCH FOUNDATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-20100323973-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | ENDOCTYE, INC. | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022245-A1 | FOLATE TARGETING OF NUCLEOTIDES | FOLR1, FOLR2, DHFR | DNM1 1906/4885MEN1 3080/4885KMT2A 1861/4885 |
| US-20130116195-A1 | Binding ligand linked drug delivery conjugates of tubulysins | TEK, TEKT1, CD2BP2 | DNM1 1023/4885MEN1 1052/4885KMT2A 3145/4885 |
| US-20160361376-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | DNM1 792/4885MEN1 186/4885KMT2A 961/4885 |
| US-20140066594-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | TEK, TEKT1, VDR | DNM1 1217/4885MEN1 1861/4885KMT2A 3742/4885 |
| US-20170266303-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | FOLR1, FOLR2, FOLH1 | DNM1 1712/4885MEN1 1102/4885KMT2A 1101/4885 |
| US-20130184435-A1 | MULTI-DRUG LIGAND CONJUGATES | VDR, CD44, HCAR1 | DNM1 1763/4885MEN1 2464/4885KMT2A 3709/4885 |
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | DNM1 792/4885MEN1 186/4885KMT2A 961/4885 |
| US-20120065149-A1 | Vitamin receptor binding drug delivery conjugates | VDR, CYP2R1, CYP24A1 | DNM1 2356/4885MEN1 3425/4885KMT2A 2852/4885 |
| US-20170151340-A1 | Conjugates Containing Hydrophilic Spacer Linkers | CD44, HAVCR2, HCAR1 | DNM1 356/4885MEN1 2245/4885KMT2A 3989/4885 |
| US-20120270791-A1 | Methods and Compositions for Treating and Diagnosing Kidney Disease | VDR, GC, CYP24A1 | DNM1 1355/4885MEN1 1833/4885KMT2A 4582/4885 |
| US-20140058064-A1 | MULTI-DRUG LIGAND CONJUGATES | VDR, CD44, HCAR1 | DNM1 1763/4885MEN1 2464/4885KMT2A 3709/4885 |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | DNM1 792/4885MEN1 186/4885KMT2A 961/4885 |
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | DNM1 792/4885MEN1 186/4885KMT2A 961/4885 |
| US-20140058063-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VDR, CYP2R1, CYP24A1 | DNM1 2356/4885MEN1 3425/4885KMT2A 2852/4885 |
| US-20160287731-A1 | Compounds for Positron Emission Tomography | FOLH1, FOLR2, FOLR1 | DNM1 2281/4885MEN1 259/4885KMT2A 1947/4885 |
| US-20100323973-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | CD44, HAVCR2, HCAR1 | DNM1 356/4885MEN1 2245/4885KMT2A 3989/4885 |
| US-20140073761-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | CD44, HAVCR2, HCAR1 | DNM1 356/4885MEN1 2245/4885KMT2A 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.